IMGT engineered variant nomenclature: Fc variants

Citing this table: Lefranc, M.-P. and Lefranc, G., The Immunoglobulin FactsBook, Academic Press, London, UK (458 pages), 2001, ISBN:012441351X

1. Structural and biological properties of human immunoglobulins

2. Human immunoglobulin (IG) chain characteristics

3. IG interchain disulfide bridges per monomer

4. Lysines and cysteines of the Homo sapiens IGHG1, IGKC and IGLC1 and positions in the C-DOMAIN

5. Amino acid positions involved in ADCC, ADCP, CDC, half-life and half-IG exchange

7. Homo sapiens IGHG1 amino acids involved in the interactions with the C1q, FcγR and FCGRT

Species IMGT gene name IMGT engineered variant nomenclature IMGT Fc variant description Property modifications IMGT Note References
IMGT Fc variant number CH1 or c-KAPPA/C-LAMBDA AA and IMGT position in CH1 of IGHG or IGKC/IGLC variant hinge (h) or CH2 AA and IMGT position in h or CH2 of IGHG variant CH3 AA and IMGT position in CH3 of IGHG variant Eu-IMGT positions Effector Half-life Structure Physicochemical properties Hybrid
Homo sapiens IGHG1 1-G1v1 CH2 P1.4 v1 CH2 P1.4 E233P ADCC reduction [1]
1-G1v1-2-3 CH2 P1.4, V1.3, A1.2 v1-2-3 CH2 P1.4, V1.3, A1.2 E233P, L234V, L235A ADCC reduction Combines 1-G1v1, 1-G1v2, and 1-G1v3 [52]
1-G1v2 CH2 V1.3 v2 CH2 V1.3 L234V ADCC reduction [1]
1-G1v3 CH2 A1.2 v3 CH2 A1.2 L235A ADCC reduction [1]
6-G1v3-1 CH2 A1.2, A1 v3-1 CH2 A1.2, A1 L235A, G237A ADCC and CDC reduction [61]
6-G1v4 CH2 A114 v4 CH2 A114 P329A ADCC and CDC reduction [2]
6-G1v4-2 CH2 R114 v4 CH2 R114 P329R ADCC and CDC reduction [2]
6-G1v4-66 CH2 A27, A114 v4-66 CH2 A27, A114 D265A, P329A ADCC and CDC reduction Combines 6-G1v4 and 1-G1v66 [41]
1,4-G1v5 CH2 W109 v5 CH2 W109 K326W ADCC reduction
CDC enhancement		 Increases C1 binding [3]
1,4-G1v5-2 CH2 A1.3, A1.2, A109, S118 v5-2 CH2 A1.3, A1.2, A109, S118 L234A, L235A, K326A, E333S ADCC reduction
CDC enhancement		 Reduces FcγR
Increases C1q binding		 [113]
2-G1v6 CH2 A85.4, A118, A119 v6 CH2 A85.4, A118, A119 S298A, E333A, K334A ADCC enhancement [4]
2-G1v7 CH2 D3, E117 v7 CH2 D3, E117 S239D, I332E ADCC enhancement [5]
2,5-G1v8 CH2 D3, L115, E117 v8 CH2 D3, L115, E117 S239D, A330L, I332E ADCC enhancement
CDC reduction		 [5]
2-G1v9 CH2 L7, P83, L85.2, I88, CH3 L83 v9 CH2 L7, P83, L85.2, I88 CH3 L83 F243L, R292P, Y300L, V305I, P396L ADCC enhancement Increases ADCC by 100% [6]
2-G1v9-1 CH2 V1.2, L7, P83, L85.2, CH3 L83 v9-1 CH2 V1.2, L7, P83, L85.2 CH3 L83 L235V, F243L, R292P, Y300L, P396L ADCC enhancement [63]
2-G1v10 CH2 Y1.3, Q1.2, W1.1, M3, D30, E34, A85.4 v10 CH2 Y1.3, Q1.2, W1.1, M3, D30, E34, A85.4 L234Y, L235Q, G236W, S239M, H268D, D270E, S298A ADCC enhancement Increases FcγIIIA binding: >2000-fold (F158), >1000-fold (V158) [7]
2-G1v11 CH2 E34, D109, M115, E119 v11 CH2 E34, D109, M115, E119 D270E, K326D, A330M, K334E
3-G1v12 CH2 A1.1, D3, L115, E117 v12 CH2 A1.1, D3, L115, E117 G236A, S239D, A330L, I332E ADCC and ADCP enhancement Increases FcγRIIIA and FcγRIIA binding [8]
3-G1v13 CH2 A1.1, D3, E117 v13 CH2 A1.1, D3, E117 G236A, S239D, I332E ADCC and ADCP enhancement Increases FcγRIIIA and FcγRIIA binding, increases FcγRIIa/FcγRIIb binding ratio [9]
6-G1v14 CH2 A1.3, A1.2 v14 CH2 A1.3, A1.2 L234A, L235A ADCC and CDC reduction Reduces FcγR and C1q binding [10]
6-G1v14-1 CH2 A1.3, A1.2, A1 v14-1 CH2 A1.3, A1.2, A1 L234A, L235A, G237A ADCC and CDC reduction Reduces FcγR and C1q binding [11]
6-G1v14-1-20 CH2 A1.3, A1.2, A1, A105 v14-1-20 CH2 A1.3, A1.2, A1, A105 L234A, L235A, G237A, K322A ADCC and CDC reduction Combines 6-G1v14-1 and 5-G1v20 [58]
6-G1v14-4 CH2 A1.3, A1.2, A114 v14-4 CH2 A1.3, A1.2, A1 L234A, L235A, P329A ADCC and CDC reduction Reduces FcγR and C1q binding [12]
6-G1v14-48 CH2 A1.3, A1.2, R113 v14-48 CH2 A1.3, A1.2, R113 L234A, L235A, L328R ADCC and CDC reduction Reduces FcγR and C1q binding
Combines 6-G1v14 and 6-G1v48		 [75]
6-G1v14-49 CH2 A1.3, A1.2, G114 v14-49 CH2 A1.3, A1.2, G114 L234A, L235A, P329G ADCC and CDC reduction Abrogates FcγR and C1q binding
Combines 6-G1v14 and 6-G1v49		 [13]
6-G1v14-67 CH2 A1.3, A1.2, S27 v14-67 CH2 A1.3, A1.2, S27 L234A, L235A, D265S ADCC and CDC reduction Reduces FcγR and C1q binding
Combines 6-G1v14 and 1-G1v67		 [14]
4-G1v15 CH2 S118 v15 CH2 S118 E333S CDC enhancement Increases C1q binding [3]
4-G1v16 CH2 W109, S118 v16 CH2 W109, S118 K326W, E333S CDC enhancement Increases C1q binding [3]
4-G1v17 CH2 E29, F30, T107 v17 CH2 E29, F30, T107 S267E, H2668F, S324T CDC enhancement Increases C1q binding [15]
4,10,13-G1v18 CH3 R1, G109, Y120 v18 CH3 R1, G109, Y120 E345R, E430G, S440Y CDC enhancement Hexamerisation Increases C1q binding by IgG1 hexamerization [16]
5-G1v19 CH2 A34 v19 CH2 A34 D270A CDC reduction Reduces C1q binding [2]
5-G1v20 CH2 A105 v20 CH2 A105 K322A CDC reduction Reduces C1q binding [2]
9-G1v21 CH2 Y15.1, T16, E18 v21 CH2 Y15.1, T16, E18 M252Y, S254T, T256E Half-life increase Enhances FCGRT binding at pH 6.0
Reduces ADCC		 [17]
9-G1v22 CH2 Y15.1, T16, E18, CH3 K113, F114, H116 v22 CH2 Y15.1, T16, E18 CH3 K113, F114, H116 M252Y, S254T, T256E, H433K, N434F, Y436H Half-life increase Enhances FCGRT binding at pH 6.0 [18]
9-G1v22-1 CH2 Y15.1, T16, E18, CH3 K113, F114 v22-1 CH2 Y15.1, T16, E18; CH3 K113, F114 M252Y, S254T, T256E, H433K, N434F Half-life decrease Enhances FCGRT binding without pH dependency [69]
6-G1v23 CH2 E1.2 v23 CH2 E1.2 L235E ADCC and CDC reduction Reduces FcγR and C1q binding [19]
9-G1v24 CH3 L107, S114 v24 CH3 L107, S114 M428L, N434S Half-life increase Enhances FCGRT binding at pH 6.0 [20]
9-G1v24-1 CH3 V107 v24-1 CH3 V107 M428V Half-life increase [56]
7-G1v25 CH2 E29, F113 v25 CH2 E29, F113 S267E, L328F B cell inhibition Increases FcγRIIb binding
Inhibits by downstream ITIM siganalling in B cells		 [21]
14-G1v26 CH3 Y22 v26 CH3 Y22 T366Y Heteropairing H-H enhancement Knob in knobs-into-holes interaction [22]
14-G1v31 CH3 T86 v31 CH3 T86 Y407T Hole in knobs-into-holes interaction
16-G1v27 CH2 C3 v27 CH2 C3 S239C Site-specific drug attachment [23]
16-G1v27-1 CH1 C1.4 v27-1 CH1 C1.4 A118C Site-specific drug attachment [109]
16-G1v28 CH2 3^4 ins^C v28 CH2 3^4 ins^C C239^240 Site-specific drug attachment Reduces ADCC [24]
8-G1v29 CH2 A84.4 v29 CH2 A84.4 N297A No N-glycosylation site (CH2 N84.4)
ADCC reduction		 Reduces FcγR binding [25]
8-G1v30 CH2 G84.4 v30 CH2 G84.4 N297G No N-glycosylation site (CH2 N84.4)
ADCC reduction		 Reduces FcγR binding [25]
8-G1v30-1 CH2 H84.4 v30-1 CH2 H84.4 N297H No N-glycosylation site (CH2 N84.4)
ADCC reduction		 Reduces FcγR binding [37]
14-G1v32 CH3 W22 v32 CH3 W22 T366W Heteropairing H-H enhancement Knob in knobs-into-holes interaction [26]
14-G1v33 CH3 S22, A24, V86 v33 CH3 S22, A24, V86 T366S, L368A, Y407V Hole in knobs-into-holes interaction
13-G1v34 CH3 G109 v34 CH3 G109 E430G Hexamerisation Increases C1q binding by form IgG1 hexamers [27]
4-G1v35 CH2 E29 v35 CH2 E29 S267E CDC enhancement Increases C1q binding [15]
8-G1v36 CH2 Q84.4 v36 CH2 Q84.4 N297Q No N-glycosylation site (CH2 N84.4)
ADCC reduction		 Reduces FcγR binding [25]
8-G1v36-1 CH2 S84.4 v36-1 CH2 S84.4 N297S No N-glycosylation site (CH2 N84.4)
ADCC reduction		 Reduces FcγR binding [49]
15-KCv36 C-KAPPA S126 v36 C-KAPPA S126 C214S Suppression of inter H-L disulfide bridge [108]
15-KCv37 C-KAPPA C121, S126 v37 C-KAPPA C121, S126 F209C, C214S Suppression of inter H-L disulfide bridge
15-G1v37 h S5 v37 h S5 C220S Suppression of inter H-H disulfide bridge [108]
15-G1v37-1 h G5 v37-1 h G5 C220G Suppression of inter H-H disulfide bridge [104]
6-G1v38 CH2 S108, F113 v38 CH2 S108, F113 N325S, L328F ADCC and CDC reduction Abrogates FcγRIII and C1q binding [29]
6-G1v39 CH2 F1.3, E1.2, S116 v39 CH2 F1.3, E1.2, S116 L234F, L235E, P331S ADCC and CDC reduction Reduces FcγR and C1q binding [96]
6-G1v40 CH2 A1.3, A1.2, S116 v40 CH2 A1.3, A1.2, S116 L234A, L235A, P331S ADCC and CDC reduction Reduces FcγR and C1q binding [31]
6-G1v41 CH2 F1.3, E1.2 v41 CH2 F1.3, E1.2 L234F, L235E ADCC and CDC reduction Reduces FcγR and C1q binding [75]
6-G1v41-66 CH2 F1.3, E1.2, A27 v41-66 CH2 F1.3, E1.2, A27 L234F, L235E, D265A ADCC and CDC reduction Combines 6-G1v41 and 1-G1v66 [59]
9-G1v42 CH2 Q14, CH3 L107 v42 CH2 Q14 CH3 L107 T250Q, M428L Half-life increase Enhances FCGRT binding at pH 6.0 [28]
6-G1v43 CH2 A1.3, E1.2, A1 v43 CH2 A1.3, E1.2, A1 L234A, L235E, G237A ADCC and CDC reduction Reduces FcγR and C1q binding [11]
6-G1v43-1 CH2 A1.3, A1 v43-1 CH2 A1.3, A1 L234A, G237A ADCC and CDC reduction [41]
6-G1v43-2 CH2 A1.3, E1.2 v43-2 CH2 A1.3, E1.2 L234A, L235E ADCC and CDC reduction [72]
6-G1v43-60 CH2 A1.3, E1.2, A1, S115, S116 v43-60 CH2 A1.3, E1.2, A1, S115, S116 L234A, L235E, G237A, A330S, P331S ADCC and CDC reduction Combines 6-G1v43 and 6-G1v60 [32]
16-G1v44 CH3 C122 v44 CH3 C122 S442C Site-specific drug attachment [33]
3-G1v45 CH2 A1.1, L115, E117 v45 CH2 A1.1, L115, E117 G236A, A330L, I332E ADCC and ADCP enhancement Increases FcγRIIIA, NK cell activation [34]
9-G1v46 CH3 K113, F114 v46 CH3 K113, F114 H433K, N434F Half-life increase Enhances FCGRT binding at pH 6.0 [35]
1-G1v47 CH2 delG1.1 v47 CH2 delG1.1 G236del ADCC reduction Abrogates FcγRI, FcγRIIA, FcγRIIIA binding [36]
6-G1v48 CH2 R113 v48 CH2 R113 L328R ADCC and CDC reduction Reduces FcγR and C1q binding [75]
6-G1v49 CH2 G114 v49 CH2 G114 P329G ADCC and CDC reduction Reduces FcγR and C1q binding [12]
1-G1v50 CH2 delE1.4, P1.3, V1.2, A1.1 v50 CH2 delE1.4, P1.3, V1.2, A1.1 E233del, L234P, L235V, G236A ADCC reduction Reduces FcγR binding (IGHG2-like motif) [75]
1-G1v50-1-4 CH2 delE1.4, P1.3, A1.2, A1.1, A114 v50-1-4 CH2 delE1.4, P1.3, V1.2, A1.1 E233del, L234P, L235A, G236A, P329A ADCC and CDC reduction
6-G1v50-4 CH2 delE1.4, P1.3, V1.2, A1.1, A114 v50-4 CH2 delE1.4, P1.3, V1.2, A1.1, A114 E233del, L234P, L235V, G236A, P329A ADCC and CDC reduction Reduces FcγR and C1q binding
Combines 1-G1v50 and 6-G1v4
6-G1v50-51 CH2 delE1.4, P1.3, V1.2, A1.1, K29 v50-51 CH2 delE1.4, P1.3, V1.2, A1.1, K29 E233del, L234P, L235V, G236A, S267K ADCC and CDC reduction Combines 1-G1v50 and 6-G1v51
1-G1v50-79 CH2 delE1.4, P1.3, V1.2, A1.1, G27, Q110, S115 v50-79 CH2 delE1.4, P1.3, V1.2, A1.1, G27, Q110, S115 E233del, L234P, L235V, G236A, D265G, A327Q, A330S ADCC reduction Combines 1-G1v50 and 1-G1v79 [113]
6-G1v51 CH2 K29 v51 CH2 K29 S267K ADCC and CDC reduction [75]
1-G1v52 CH2 R1.1, R113 v52 CH2 R1.1, R113 G236R, L328R ADCC reduction Abrogates FcγR binding [59]
6-G1v53 CH2 F1.3, Q1.2, Q105 v53 CH2 F1.3, Q1.2, Q105 L234F, L235Q, K322Q ADCC and CDC reduction Reduces FcγR and C1q binding [38]
6-G1v53-1 CH2 A1.3, Q1.2, Q105 v53-1 CH2 A1.3, Q1.2, Q105 L234A, L235Q, K322Q ADCC and CDC reduction [57]
11-G1v54 CH2 C83, C85 v54 CH2 C83, C85 R292C, V302C Additionalinter H-H disulfide bridge Stabilizes aglycosylated antibodies [39]
11,8-G1v54-29 CH2 C83, A84.4, C85 v54-29 CH2 C83, A84.4, C85 R292C, N297A, V302C Additional iinter H-H disulfide bridge Stabilizes aglycosylated antibodies
Combines 11-G1v54 and 8-G1v29		 [39]
11,8-G1v54-30 CH2 C83, G84.4, C85 v54-30 CH2 C83, G84.4, C85 R292C, N297G, V302C Additional inter H-H disulfide bridge Stabilizes aglycosylated antibodies
Combines 11-G1v54 and 8-G1v30		 [39]
11,8-G1v54-36 CH2 C83, Q84.4, C85 v54-36 CH2 C83, Q84.4, C85 R292C, N297Q, V302C Additional inter H-H disulfide bridge Stabilizes aglycosylated antibodies
Combines 11-G1v54 and 8-G1v36		 [39]
16-G1v55 CH2 C123 v55 CH2 C123 L443C Site-specific drug attachment [33]
16-G1v56 CH1 F(pAMF)85.2, CH3 F(pAMF)85.2 v56 CH1 F(pAMF)85.2 CH3 F(pAMF)85.2 Y180F (pAMF), F404F (pAMF) Site-specific drug attachment [40]
16-G1v56-1 CH1 F(pAF)1.4 v56-1 CH1 F(pAF)1.4 A118F (pAF) Site-specific drug attachment [99]
16-G1v56-2 CH3 F(pAMF)85.2 v56-2 CH3 F(pAMF)85.2 F404F (pAMF) Site-specific drug attachment [112]
17-G1v57 CH1 E26, E119 v57 CH1 E26, E119 K147E, K213E Heteropairing H-L enhancement [75]
17-KCv57 C-KAPPA R12, K13 v57 C-KAPPA R12, K13 E123R, Q124K
17-G1v57-3 CH1 D26 v57-3 CH1 D26 K147D Heteropairing H-L enhancement [104]
17-KCv57-3 C-KAPPA K20 v57-3 C-KAPPA K20 S131K
17-G1v58 CH1 C5, h V5 v58 CH1 C5 h V5 F126C, C220V Heteropairing H-L enhancement [75]
17-LC2v58 C-LAMBDA2 C10, V126 v58 C-LAMBDA2 C10, V126 S121C, C214V
6-G1v59 CH2 S1.3, T1.2, R1.1 v59 CH2 S1.3, T1.2, R1.1 L234S, L235T, G236R ADCC and CDC reduction Abrogates FcγR and C1q binding
ADCC and CDC undetectable		 [41]
6-G1v59-1 CH2 G1.2, R1.1 v59-1 CH2 G1.2, R1.1 L235G, G236R ADCC and CDC reduction [62]
6-G1v59-2 CH2 R1.2, R1.1, K3 v59-2 CH2 R1.2, R1.1, K3 L235R, G236R, S239K ADCC and CDC reduction [67]
6-G1v60 CH2 S115, S116 v60 CH2 S115, S116 A330S, P331S ADCC and CDC reduction Reduces FcγR and C1q binding [41]
6-G1v60-1 CH2 G110, S115, S116 v60-1 CH2 G110, S115, S116 A327G, A330S, P331S ADCC and CDC reduction
15-G1v61 h S11 v61 h S11 C226S Suppression of inter H-H disulfide bridge [75]
15-G1v62 h S14 v62 h S14 C229S Suppression of inter H-H disulfide bridge [75]
6-G1v63 CH2 S2 v63 CH2 S2 P238S ADCC and CDC reduction Reduces FcγR and C1q binding [75]
6,7-G1v63-2 CH2 D2 v63-2 CH2 D2 P238D ADCC reduction
B cell inhibition		 Reduces FcγR and C1q binding
Increases FcγRIIb binding
Inhibits by downstream ITIM siganalling in B cells		 [113]
6,7-G1v63-3 CH2 D1.4, D1, D2, D30, G35, R115 v63-3 CH2 D1.4, D1, D2, D30, G35, R115 E233D, G237D, P238D, H268D, P271G, A330R ADCC reduction
B cell inhibition		 Reduces FcγR and C1q binding
Increases FcγRIIb binding
Inhibits by downstream ITIM siganalling in B cells		 [113]
16-G1v64 CH2 C36 v64 CH2 C36 E272C Site-specific drug attachment [42]
6-G1v65 CH2 delE1.4, delL1.3, delL1.2 v65 CH2 delE1.4, delL1.3, delL1.2 E233del, L234del, L235del ADCC and CDC reduction Reduces FcγR and C1q binding [43]
1-G1v66 CH2 A27 v66 CH2 A27 D265A ADCC reduction Reduces FcγR binding [75]
1-G1v66-80 CH2 A27, G116 v66-80 CH2 A27, G116 D265A, P331G ADCC reduction
1-G1v67 CH2 S27 v67 CH2 S27 D265S ADCC reduction Reduces FcγR binding [75]
14-G1v68 CH3 V6, L22, L79, W81 v68 CH3 V6, L22, L79, W81 T350V, T366L, K392L, T394W Heteropairing H-H enhancement [44]
14-G1v69 CH3 V6, Y7,A85.1, V86 v69 CH3 V6, Y7,A85.1, V86 T350V, L351Y, F405A, Y407V
17-G1v68-1 CH1 E7, T26, E84.2 v68-1 CH1 E7, T26, E84.2 L128E, K147T, Q175E Heteropairing H-L enhancement [76]
17-KCv68-1 C-KAPPA R20, G22, R86 v68-1 C-KAPPA R20, G22, R86 S131R, V133G, S176R
17-G1v69-1 CH1 K86 v69-1 CH1 K86 S183K Heteropairing H-L enhancement
17-LC2v69-1 C-LAMBDA2 E86, E88, A124 v69-1 C-LAMBDA2 E86, E88, A124 S176E, Q178E, T212A
15-G1v70 h S5, S11, S14 v70 h S5, S11, S14 C220S, C226S, C229S Suppression of inter H-H disulfide bridge [45]
14-G1v72 CH3 D7, E24 v72 CH3 D7, E24 L351D, L368E Heteropairing H-H enhancement Heteropairing by electrostatic steering effects [66]
14-G1v73 CH3 K7, K22 v73 CH3 K7, K22 L351K, T366K
14-G1v72-1 CH3 E7, L86, V88 v72-1 CH3 E7, L86, V88 L351E, Y407L, K409V Heteropairing H-H enhancement [68]
14-G1v73-1 CH3 L22, R84.2 v73-1 CH3 L22, R84.2 T366L, D399R
14-G1v72-2 CH3 D79, D88 v72-2 CH3 D79, D88 K392D, K409D Heteropairing H-H enhancement Heteropairing by electrostatic steering effects [70]
14-G1v73-2 CH3 K12, K84.2 v73-2 CH3 K12, K84.2 E356K, D399K
14-G1v74 CH3 C10 v74 CH3 C10 S354C Heteropairing H-H enhancement Additional inter H-H disulfide bridge for domain stabilization [50]
14-G1v75 CH3 C5 v75 CH3 C5 Y349C
16-G1v76 CH2 C27 v76 CH2 C27 D265C Site-specific drug attachment Reduce FcγR binding
9-G1v77 CH3 A115 v77 CH3 A115 H435A Half-life decrease [113]
9-G1v77-1 CH2 A15.2, A93, CH3 A115 v77-1 CH2 A15.2, A93 CH3 A115 I253A, H310A, H435A Half-life decrease [55]
9-G1v77-2 CH2 K17 v77-2 CH2 K17 R255K Half-life decrease [104]
9-G1v78 CH3 L107, A114 v78 CH3 L107, A114 M428L, N434A Half-life increase [60]
9-G1v78-1 CH3 L107, A114, T116 v78-1 CH3 L107, A114, T116 M428L, N434A, Y436T Half-life increase [113]
9-G1v78-2 CH3 A114 v78-2 CH3 A114 N434A Half-life increase [113]
9-G1v78-3 CH3 K115 v78-3 CH3 K115 H435K Half-life increase [54]
1-G1v79 CH2 G27, Q110, S115 v79 CH2 G27, Q110, S115 D265G, A327Q, A330S ADCC reduction [113]
1-G1v80 CH2 G116 v80 CH2 G116 P331G ADCC reduction [113]
16-G1v81 CH2 C81 v81 CH2 C81 K290C Site-specific drug attachment [89]
16-KCv93 C-KAPPA C93 v93 C-KAPPA C93 K183C Site-specific drug attachment [89]
18-G1v82-1 CH3 L85.1 v82-1 CH3 L85.1 F405L Control of bispecific H-H heteropairing [51]
18-G1v82-2 CH3 R88 v82-2 CH3 R88 K409R
14-G1v82-3 CH3 K85.1 v82-3 CH3 K85.1 F405K Heteropairing H-H enhancement [71]
14-G1v82-4 CH3 A88 v82-4 CH3 A88 K409A
18-G1v82-5 CH3 D24, S26 v82-5 CH3 D24, S26 L368D, K370S Control of bispecific H-H heteropairing Fc heterodimer purification enhancement [65]
18-G1v82-6 CH3 Q13, K20 v82-6 CH3 Q13, K20 E357Q, S364K
18-G1v82-7 CH3 R84.2, E88 v82-7 CH3 R84.2, E88 D399R, K409E Control of bispecific H-H heteropairing Expression of two different antibodies in a single cell
Heteropairing H-H reduction		 [104]
10-G1v83 CH3 R115, F116 v83 CH3 R115, F116 H435R, Y436F Protein A binding abrogation [97]
10-G1v83-1 CH3 R115 v83-1 CH3 R115 H435R Protein A binding abrogation [98]
11-G1v84 CH1 C81, C84 v84 CH1 C81, C84 F170C, V173C Additional inter H-L and/or inter H-H disulfide bridge [104]
11-KCv84 C-KAPPA C79, C81 v84 C-KAPPA C79, C81 Q160C, S162C
17-G1v84-1 VH E44, CH1 K86 v84-1 VH
CH1		 E44
K86		 Q44E, S183K Heteropairing H-L enhancement
17-Kv84-1 V-KAPPA K44, C-KAPPA E22 v84-1 V-KAPPA
C-KAPPA		 K44
E22		 Q44K, V133E
17-G1v84-2 VH K44, CH1 E86 v84-2 VH
CH1		 K44
E86		 Q44K, S183E Heteropairing H-L enhancement
17-Kv84-2 V-KAPPA E44, C-KAPPA K22 v84-2 V-KAPPA
C-KAPPA		 E44
K22		 Q44E, V133K
7-G1v85 CH2 W1.2, N1.1, D30, K115 v85 CH2 W1.2, N1.1, D30, K115 L235W, G236N, H268D, A330K B cell inhibition Increases FcγRIIb binding
Inhibits by downstream ITIM siganalling in B cells		 [113]
7-G1v86 CH2 Y1.3, D2, I26, K115 v86 CH2 Y1.3, D2, I26, K115 L234Y, P238D, V264I, A330K ADCC reduction
B cell inhibition		 Reduces FcγR and C1q binding
Increases FcγRIIb binding
Inhibits by downstream ITIM siganalling in B cells		 [113]
10-G1v87 CH2 V14, P90 v87 CH2 V14, P90 T250V, T307P Thermal stability [113]
10-G1v88 CH2 R94, CH3 R1.2 v88 CH2 R94 CH3 R1.2 Q311R, P343R pI engineering Increases pI for enhanced uptake of immune complexes [113]
10-G1v88-1 CH2 R94, CH3 K92 v88-1 CH2 R94 CH3 K92 Q311R, D413K pI engineering Increases pI for enhanced uptake of immune complexes [113]
10-G1v89 CH3 R118, E120 v89 CH3 R118, E120 Q438R, S440E Suppression of rheumatoid factor binding [73]
14-G1v90 CH3 E16, W88 v90 CH3 E16, W88 K306E, K409W Heteropairing H-H enhancement Knob in knobs-into-holes interaction
14-G1v91 CH3 R3, V84.2, T85.1 v91 CH3 R3, V84.2, T85.1 Q347R, D399V, F405T Hole in knobs-into-holes interaction
17-G1v92-1 VH E44, CH1 E77 v92-1 VH
CH1		 E44
E77		 Q44E, G166E Heteropairing H-L enhancement
17-Kv92-1 V-KAPPA K44, C-KAPPA K3 v92-1 V-KAPPA
C-KAPPA		 K44
K3		 Q44K, S114K
17-G1v92-2 VH K44, CH1 K77 v92-2 VH
CH1		 K44
K77		 Q44K, G166K Heteropairing H-L enhancement
17-Kv92-2 V-KAPPA E44, C-KAPPA E3 v92-2 V-KAPPA
C-KAPPA		 E44
E3		 Q44E, S114E
11-G1v93 CH1 C12 v93 CH1 C12 K133C Additional inter H-L and/or inter H-H disulfide bridge
11-G1v94 CH1 C94 v94 CH1 C94 S191C Additional inter H-L and/or inter H-H disulfide bridge Restrict flexibility in the CH1 domain
17-KCv96 C-KAPPA A1.4, S1.3 v96 C-KAPPA A1.4, S1.3 R108A, T109S Heteropairing H-L enhancement
6-G1v97 CH2 A1.3, A1.2, A1, S2, A30, S115, S116 v97 CH2 A1.3, A1.2, A1, S2, A30, S115, S116 L234A, L235A, G237A, P238S, H268A, A330S, P331S ADCC and CDC reduction Reduces FcγR and C1q binding
Undetectable ADCC, CDC and ADCP		 [113]
10,13-G1v98 CH3 R1 v98 CH3 R1 E345R Hexamerisation
14-G1v99-1 h E6, CH3 E24 v99-1 h E6 CH3 E24 D221E, L368E Heteropairing H-H enhancement
14-G1v99-2 h R6, CH3 R88 v99-2 h R6 CH3 R88 D221R, K409R
10-G1v100-1 CH1 E16 v100-1 CH1 E16 G137E pI engineering Reduces pI for thermal stability
1-G1v101 CH2 R31 v101 CH2 R31 E269R ADCC reduction
1,5-G1v101-20 CH2 R31, A105 v101-20 CH2 R31, A105 E269R, K322A ADCC and CDC reduction Combines 1-G1v101 and 5-G1v20 [53]
2-G1v102 CH3 M81 v102 CH3 M81 T394M ADCC enhancement
2-G1v103 CH2 I11, Q124 v103 CH2 I11, Q124 P247I, A339Q ADCC enhancement [64]
3-G1v104 CH2 A85.3 v104 CH2 A85.3 T299A ADCC and ADCP enhancement Increases FcγRIIa binding and moderate binding to FcγRIIIa in aglycosylated antibodies [37]
7-G1v105 CH3 P85.3 v105 CH3 P85.3 S403P B cell inhibition Increases FcγRIIb binding
Inhibits downstream ITIM siganalling in B cells		 [74]
1-G1v106 CH2 E37 v106 CH2 E37 V273E ADCC reduction
B cell inhibition		 Increases FcγRIIa and FcγRIIb binding [48]
10-G1v108 CH1 D114, CH2 E84.2, CH3 D44, E97, D100 v108 CH1 D114 CH2 E84.2 CH3 D44, E97, D100 N208D Q295E, N384D, Q418E, N421D Fc heterodimer with one chain remaining unmutated Heteropairing H-H enhancement [65]
5-G1v120 CH2 V115 v120 CH2 V115 A330V CDC reduction [114]
IGHG2 2-G2v1 CH2 P1.4, L1.3, L1.2, G1.1 v1 CH2 P1.4, L1.3, L1.2, G1.1 P234L, V235L, A237G ADCC enhancement Homsap IGHG1 like [1]
6-G2v2 CH2 Q30, L92, S115, S116 v2 CH2 Q30, L92, S115, S116 H268Q, V309L, A330S, P331S ADCC and CDC reduction Reduces FcγR and C1q binding [78]
6-G2v3 CH2 A1.2, A1, S2, A30, L92, S115, S116 v3 CH2 A1.2, A1, S2, A30, L92, S115, S116 V235A, G237A, P238S, H268A, V309L, A330S, P331S ADCC and CDC reduction Reduces FcγR and C1q binding
Undetectable ADCC, ADCP and CDC		 [30]
6-G2v3-1 CH2 A1.2, A1 v3-1 CH2 A1.2, A1 V235A, G237A ADCC and CDC reduction [116]
9-G2v4 CH2 Q14 v4 CH2 Q14 T250Q Half-life increase Enhances FCGRT binding at pH 6.0 [79]
9-G2v5 CH3 L107 v5 CH3 L107 M428L Half-life increase Enhances FCGRT binding at pH 6.0 [79]
9-G2v6 CH2 Q14, CH3 L107 v6 CH2 Q14 CH3 L107 T250Q, M428L Half-life increase Enhances FCGRT binding at pH 6.0 [79]
6,10-G2v7 CH2 Y85.2, L92, A339 v7 CH2 Y85.2, L92, A339 F300Y, V309L, T339A ADCC and CDC reduction Acid-induced aggregation reduction Low FcγR and C1q binding [80]
2-G2v7-1 CH2 D3, A110, E117 v7-1 CH2 D3, A110, E117 S239D, G327A, I332E ADCC enhancement [86]
9-G2v8-1 CH2 A93 v8-1 CH2 A93 H310A Half-life decrease Abrogates FCGRT binding at pH 6.0 [47]
5-G2v9 CH2 S116 v9 CH2 S116 P331S CDC reduction [114]
5-G2v20 CH2 A105 v20 CH2 A105 K322A CDC reduction [2]
8-G2v36 CH2 Q84.4 v36 CH2 Q84.4 N297Q No N-glycosylation site (CH2 N84.4)
ADCC reduction		 Reduces FcγR binding [83]
8,10-G2v36-104 CH2 A84.3, Q84.4 v36-104 CH2 A84.3, Q84.4 F296A, N297Q No N-glycosylation site (CH2 N84.4)
ADCC reduction		 T-cell epitope elimination Eliminates a T-cell epitope generated by the Q84.4 modification in the CH2 domain [83]
15-G2v37 h S4 v37 h S4 C219S Suppression of inter H-H disulfide bridge [84]
6-G2v60 CH2 S115, S116 v60 CH2 S115, S116 A330S, P331S ADCC and CDC reduction [81]
6-G2v60-66 CH2 A27, S115, S116 v60-66 CH2 A27, S115, S116 D265A, A330S, P331S ADCC and CDC reduction [46][81]
14-G2v72-1 h E5, E10, CH3 E24 v72-1 h E5, E10 CH3 E24 C220E, P228E, L368E Heteropairing H-H enhancement Heteropairing by electrostatic steering effects [82]
14-G2v73-1 h R5, R7, R10, CH3 R88 v73-1 h R5, R7, R10 CH3 R88 C220R, E224R, P228R, K409R
14-G2v72-2 CH3 E26, E88 v72-2 CH3 E26, E88 K370E, K409E Heteropairing H-H enhancement Heteropairing by electrostatic steering effects [85]
14-G2v73-2 CH3 K13, K84.2 v73-2 CH3 K13, K84.2 E357K, D399K
15-G2v97 CH1 S10 v97 CH1 S10 C131S Suppression of inter H-H disulfide bridge
IGHG3 9-G3v1 CH3 H115 v1 CH3 H115 R435H Half-life increase [77]
IGHG4 2-G4v1 CH2 L1.3 v1 CH2 L1.3 F234L ADCC enhancement Increases FcγRI affinity [1]
4-G4v2 CH2 P116 v2 CH2 P116 S331P CDC enhancement Homsap IGHG1, IGHG2, IGHG3 like [88]
6-G4v3 CH2 E1.2 v3 CH2 E1.2 L235E ADCC and CDC reduction Reduces FcγR and C1q binding [19]
6-G4v3-49 CH2 E1.2, G114 v3-49 CH2 E1.2, G114 L235E, P329G ADCC and CDC reduction Reduces FcγR and C1q binding
Combines 6-G4v3 and 6-G4v49		 [12]
6-G4v4 CH2 A1.3, A1.2 v4 CH2 A1.3, A1.2 F234A, L235A ADCC and CDC reduction Reduces FcγR and C1q binding [10]
6-G4v4-1 CH2 A1.2 v4-1 CH2 A1.2 L235A ADCC and CDC reduction [115]
12-G4v5 h P10 v5 h P10 S228P IgG4 half-IG exchange reduction [90]
12-G4v6 CH3 K88 v6 CH3 K88 R409K IgG4 half-IG exchange reduction [91]
6-G4v7 CH2 E1.4del, P1.3, V1.2, A1.1 v7 CH2 E1.4del, P1.3, V1.2, A1.1 E233del, F234P, L235V, G236A ADCC and CDC reduction [75]
10-G4v8 CH3 R115, F116, P125 v8 CH3 R115, F116, P125 H435R, Y436F, L445P Protein A binding abrogation [75]
10-G4v8-1 CH3 P125 v8-1 CH3 P125 L445P Acid-induced aggregation reduction [105]
6-G4v9 CH2 P1.4, V1.3, A1.2 v9 CH2 P1.4, V1.3, A1.2 E233P, F234V, L235A ADCC and CDC reduction [113]
6,1-G4v9-66 CH2 P1.4, V1.3, A1.2, A27 v9-66 CH2 P1.4, V1.3, A1.2, A27 E233P, F234V, L235A, D265A ADCC and CDC reduction Combines 6-G4v9 and 1-G4v66 [95]
18-G4v10 CH3 L85.1, K88 v10 CH3 L85.1, K88 F405L, R409K Bispecific IgG4 half-IG exchange control [92]
18,10,9-G4v11 CH1 Q100, CH2 Y84.3 v11 CH1 Q100 CH2 Y84.3 K196Q, F296Y pI engineering Incorporates two amino acids from IGHG1 into both chains of bispecific IgG4 antibodies, replacing the original IGHG4 residues, to enhance Fc heterodimer purification [103]
14-G4v12 CH3 K12 v12 CH3 K12 E356K Heteropairing H-H enhancement [103]
14-G4v13 CH3 E119 v13 CH3 E119 K439E
9-G4v21 CH2 Y15.1, T16, E18 v21 CH2 Y15.1, T16, E18 M252Y, S254T, T256E Half-life increase Enhances FCGRT binding at pH 6.0 [93]
9-G4v22 CH2 T16, P91, CH3 A114 v22 CH2 T16, P91 CH3 A114 M252Y, V308P, N434A Half-life increase Enhances FCGRT binding at pH 6.0 [94]
9-G4v24 CH3 L107, S114 v24 CH3 L107, S114 M428L, N434S Half-life increase Enhances FCGRT binding at pH 6.0 [93]
8-G4v30 CH2 G84.4 v30 CH2 G84.4 N297G No N-glycosylation site (CH2 N84.4)
ADCC reduction		 Reduces FcγR binding
14-G4v32 CH3 W22 v32 CH3 W22 T366W Heteropairing H-H enhancement Knob in knobs-into-holes interaction [26]
14-G4v33 CH3 S22, A24, V86 v33 CH3 S22, A24, V86 T366S, L368A, Y407V Hole in knobs-into-holes interaction
6-G4v34 CH2 A1.3, A1.2, A1, S2 v34 CH2 A1.3, A1.2, A1, S2 F234A, L235A, G237A, P238S ADCC and CDC reduction [113]
6-G4v35 CH2 A1.3, A1.2, delG1.1, A1, S2 v35 CH2 A1.3, A1.2, delG1.1, A1, S2 F234A, L235A, G236del, G237A, P238S ADCC and CDC reduction [113]
8-G4v36 CH2 Q84.4 v36 CH2 Q84.4 N297Q No N-glycosylation site (CH2 N84.4)
ADCC reduction		 Reduces FcγR binding [12]
9-G4v42 CH2 Q14, CH3 L107 v42 CH2 Q14 CH3 L107 T250Q, M428L Half-life increase
6-G4v49 CH2 G114 v49 CH2 G114 P329G ADCC and CDC reduction Reduces FcγR and C1q binding [12]
17-G4v57-1 CH1 K84.2 v57-1 CH1 K84.2 Q180K Heteropairing H-L enhancement
17-KCv57-1 C-KAPPA E20, E90 v57-1 C-KAPPA E20, E90 S131E, T180E
17-G4v57-2 CH1 E26, E84.2 v57-2 CH1 E26, E84.2 K147E, Q175E Heteropairing H-L enhancement
17-LC2v57-2 C-LAMBDA-2 K20, K90 v57-2 C-LAMBDA-2 K20, K90 T131K, S180K
1-G4v66 CH2 A27 v66 CH2 A27 D265A ADCC reduction [113]
9-G4v78 CH3 L107, A114 v78 CH3 L107, A114 M428L, N434A Half-life increase
10-G4v83 CH3 R115, F116 v83 CH3 R115, F116 H435R, Y436F Protein A binding abrogation [97]
10-G4v83-1 CH3 R115 v83-1 CH3 R115 H435R Protein A binding abrogation [103]
10-G4v89 CH3 R118, E120 v89 CH3 R118, E120 Q438R, S440E Suppression of rheumatoid factor binding [73]
15-G4v97 CH1 S10 v97 CH1 S10 C131S Suppression of inter H-L disulfide bridge
10-G4v111 CHS delG1, delK2 v111 CHS delG1, delK2 G446del, K447del IgG4 C-terminal heterogeneity reduction [103]
IGHG1-IGHG2 19-G1G2v1 v1 G1 CH1-h-CH2 N-terminus
G2 CH2-CH3		 Hybrid IgG1-IgG2 mAb for improving stability [107]
19-G1G2v2 v2 G2 CH1
G1 h
G2 CH2-CH3		 Hybrid IgG1-IgG2 mAb for improving stability and flexibility [110]
IGHG1-IGHG3 19-G1G3v1 v1 G1 CH1-h
G3 CH2-CH3		 Hybrid IgG1-IgG3 mAb for improving CDC Increases C1q binding [87]
IGHG1-IGHG4 19-G1G4v1 v1 G1 CH1-h
G4 CH2-CH3		 Hybrid IgG1-IgG4 mAb for improving stability and reducing effector functions
19-G1G4v2 v2 G4 CH1-h-CH2
G1 CH3		 Hybrid IgG1-IgG4 mAb for improving stability and reducing effector functions [vixarelimab]
19-G1G4v3 v3 G4 CH1
G1 h		 Hybrid IgG1-IgG4 mAb for improving flexibility Fab mAb format
IGHG2-IGHG4 19-G2G4v1 v1 G2 CH1-h-CH2 N-terminus
G4 CH2-CH3		 Hybrid IgG2-IgG4 mAb for reducing effector functions [111]
19-G2G4v2 v2 G2 CH1-h-CH2
G4 CH3		 Hybrid IgG2-IgG4 mAb for reducing effector functions [111]
C-LAMBDA-2 10-LC2v1 C-LAMBDA-2 G45, K82 v1 C-LAMBDA-2 G45, K82 S152G, T163K Improve domain stability [106]
J-CHAIN 9-Jchain-v1 A103 v1 JCHAIN A103 Y103A Half-life decrease Reduces IgM binding. Faster clearence
VH - VL 11-scFv-v1 C49 (VH)-C120 (VL) v1 VH
VL		 C49
C120		 G49C, G120C Additional disulfide bridge for domain stabilization Additional dissulfide bridge to stabilize the scFv
VL - VH
11-scFv-v2 C120 (VL)-C49 (VH) v2 VL
VH		 C120
C49		 G49C, G120C Additional disulfide bridge for domain stabilization Additional dissulfide bridge to stabilize the scFv
Mus musculus IGHG2B
Musmus 2-G2Bv1 CH2 L1.2 v1 CH2 L1.2 E235L ADCC enhancement Increases FcγRI affinity [100]
Musmus 5-G2Bv2 CH2 A101 v2 CH2 A101 E318A CDC reduction Reduces C1q binding
CH2 E101, K103 and K105 form a common core in the interactions of IgG and C1q		 [101]
Musmus 5-G2Bv3 CH2 A103 v3 CH2 A103 K320A CDC reduction Reduces C1q binding
CH2 E101, K103 and K105 form a common core in the interactions of IgG and C1q		 [101]
Musmus 5-G2Bv4 CH2 A105 v4 CH2 A105 K322A CDC reduction Reduces C1q binding
CH2 E101, K103 and K105 form a common core in the interactions of IgG and C1q		 [101]
C-KAPPA
Musmus 15-KCv36 C-KAPPA S126 v36 C-KAPPA S126 C214S Suppression of inter H-L disulfide bridge
Canis lupus familiaris IGHG2
Canlupfam 6-G2v1 CH2 A1.3, A1.2, A1 v1 CH2 A1.3, A1.2, A1 M234A, L235A, G237A ADCC and CDC reduction Reduces FcγR and C1q binding [75]
Canlupfam 6-G2v2 CH2 A1.3, A1.2, G114 v2 CH2 A1.3, A1.2, G114 M234A, L235A, P329G ADCC and CDC reduction Reduces FcγR and C1q binding [75]
Canlupfam 8-G2v29 CH2 A84.4 v29 CH2 A84.4 N297A No N-glycosylation site (CH2 N84.4)
ADCC reduction		 Reduces FcγR binding [102]
Canlupfam 8,6-G2v29-66 CH2 A27, A84.4 v29-66 CH2 A27, A84.4 D265A, N297A No N-glycosylation site (CH2 N84.4)
ADCC and CDC reduction		 [102]


Fc Variants with Unknown Effects
Fc Mutations for which no biological effects are reported in the literature are classified as having "unknow effects". To ensure the database remains up to date, automated literature mining is performed monthly to identify any newly published studies that may provide functional insights. When such variants are identified, a new IMGT nomenclature is assinged. If no functional data is found through this process, the variant remains categorized as having unknown effects.

Species IMGT gene name Provisional IMGT nomenclature IMGT numbering Eu numbering Probable effect Monoclonal antibodies carrying the mutation New IMGT engineered variant nomenclature Updated Effect Reference
Homo sapiens IGLC2 unk-1 C-LAMBDA2 G43 A150G anetumab, teclistamab, xentuzumab
IGKC unk-2 C-KAPPA A1.3 D1.2 T109A, V110D bavituximab
IGHG1 unk-3 CH3 T125 P445T canvircept
IGLC2 unk-4 C-LAMBDA2 S1.5 G107S cinpanemab
IGLC2 unk-5 C-LAMBDA2 A124 T212A cixutumumab, lodapolimab
IGHG1 unk-6 h L13, CH3 A80 P228L, T393A ADCC enhancement conbercept
IGHG1 unk-7 CH1 A121 V215A ADCC and CDC reduction derlotuximab, frexalimab, galiximab
IGLC2 unk-8 C-LAMBDA2 T3 S114T galiximab
IGHG1 unk-9 CH3 K15, T16 T359K, K360T efaprinermin alfa
IGHG4 unk-10 h ^1 ins^A A215^216 efdelikofusp alfa, efzilonkofusp alfa
IGHD-IGHG4 unk-11 IgD h-CH2-G4 CH2-CH3 efineptakin alfa, efmedaglutide alfa
IGHG4 unk-12 CH2 Y15.1, CH3 L107 M252Y, M428L Half-Life increase efdoralprin alfa
IGHG1 unk-13 h L5 C220L inter H-L disulfide bridge suppression efgivanermin alfa
IGHG1 unk-14 CH1 P85.3 L179P ensituximab
IGHG1 unk-15 CH1 A119 K213A eptinezumab
IGHG1 unk-16 CH3 delY116 Y436del Half-life increase, Protein A binding abrogation iratumumab
IGHD unk-17 h G43, S44 K192G, E193S lesigercept
IGHG1 unk-18 CH1 A10 S131A lucatumumab
IGHG4 unk-19 CH2 P13 D249P metelimumab
IGKC unk-20 C-KAPPA delS114 S202del metelimumab
IGHG2 unk-21 CH1 S10, K12, CH2 Q30 C131S, R133K, H268Q ADCC and CDC reduction nemolizumab, satralizumab
IGHG4 unk-22 CH3 M84 V397M nemolizumab
IGHG1 unk-23 CH1 L5 F126L necitumumab, ramucirumab
IGKC unk-24 C-KAPPA E1.3 T109E nimotuzumab
IGKC unk-25 C-KAPPA S1.3 T109S olinvacimab, ulenistamab
IGHG1 unk-26 CH3 F85.3 S403F B cell inhibition ontuxizumab
IGLC3 unk-27 C-LAMBDA3 delG1.5, R119, L123, delS127 G107Adel, K207R, P211L, S215del opucolimab
IGHG1 unk-28 CH1 L3 S124L ormutivimab
IGLC2 unk-29 C-LAMBDA2 R1.5 G107R otelixizumab
IGKC unk-30 C-KAPPA A1.3 T109A prafnosbart
IGKC unk-32 C-KAPPA G1.4 R108G ramucirumab
IGHG4 unk-33 CH3 M84, A114 V397M, N434A Half-life increase satralizumab
IGKC unk-34 C-KAPPA A1.3, D1.2, T3, delR123, delG124, delE125, delC126 T109A, V110D, S114T, R211del, G212del, E213del, C214del satumomab
IGHG4*01-IGHG2A*01 unk-35 human G4 CH1- Mouse G2A CH2-CH3 satumomab
IGHG1 unk-36 CH3 G84.4, D85.4 D401G, G402D silevimig
IGHG1 unk-37 h delK7, C8, delT10 K222del, T223C, T225del Inter H-H disulfide bridge addition telisotuzumab
IGHG1 unk-38 CH3 Y44, delQ45.1, T45.2, W45.4, ^45.7 ins^A, T92, E94, E95, F100 N384Y, Q386del, P387T, N389W, A389^390, D413T, S415E, R416E, N421F tividenofusp alfa
IGKC unk-39 C-KAPPA delR1.4 R108del urabrelimab
IGHG1 unk-40 CH1 S1.4 A118S ustekinumab
IGHG2 unk-41 CHS S1 G446S visilizumab
Canis lupus familiares IGHG2 Canlupfam unk-1 CH1 Q14 T135Q blontuvetmab
IGKC Canlupfam unk-2 C-KAPPA ^84.3 ins^S S167^168 gilvetmab
IGHG2 Canlupfam unk-3 CH3 H114 N434H riltovetbart
Felis catus IGHG1 Felcat unk-1 CH2 A1.3, A1.2, A1 M234A, L235A, G237A ADCC and CDC reduction dovanvetmab
IGKC Felcat unk-2 C-KAPPA Q122, delQ127, delR128, delE129 N210Q, Q215del, R216del, E217del dovanvetmab
IGKC Felcat unk-3 C-KAPPA Q122 N210Q relfovetmab
Mus musculus IGHG1 Musmus unk-2 CH1 E100, CH2 Q81, delS85, F84.3, CH3 D27 Q196E, K290Q, I296F, S302del, N371D apamistamab
IGHG1 Musmus unk-3 CH1 Q84.2 E175Q lemalesomab, racotumomab
IGHG1 Musmus unk-4 CH1 Q84.2, T95, W96, CH3 D84.2, D84.4 E175Q, P192T, R193W, N399D, N401D lilotomab
IGHG1 Musmus unk-5 CH1 E100, CH2 Q81, F84.3, CH3 D27 Q196E, K290Q, I296F, N371D miromavimab, omburtamab
IGHG2A Musmus unk-6 CH1 G13 D134G muromonab-CD3
IGKC Musmus unk-7 C-KAPPA T1.1 A111T muromonab-CD3
IGHG1 Musmus unk-8 CH1 E100 Q196E nacolomab
IMGT references:
  • [1] Chappel M.S. et al., Proc Natl Acad Sci U S A, 88(20):9036-9040 (1991). PMID: 1833770
  • [2] Idusogie E.E. et al., J Immunol, 164(8):4178-4184 (2000). PMID: 10754313
  • [3] Idusogie E.E. et al., J Immunol, 166(4):2571-2575 (2001). PMID: 11160318
  • [4] Shields R.L. et al., J Biol Chem, 276(9):6591-6604 (2001). PMID: 11096108
  • [5] Lazar G.A. et al., Proc Natl Acad Sci U S A, 103(11):4005-4010 (2006). PMID: 16537476
  • [6] Stavenhagen J.B. et al., Cancer Res, 67:8882-8890 (2007). PMID: 17875730
  • [7] Mimoto F. et al., Mabs, 5: 229-236 (2013). PMID: 23406628
  • [8] Ahmed A et al. J Struct Biol 1:78-89 (2016). PMID: 26850169
  • [9] Richards J.O., Mol Cancer Ther, 7(8):2517-2527 (2008). PMID: 18723496
  • [10] Xu D. et al., Cell Immunol, 200:16-26 (2000). PMID: 10716879
  • [11] Hezareh M et al. J Virol, 75(24):12161-8 (2001). PMID: 11711607
  • [12] Schlothauer T. et al. Protein Eng Des Sel, 29(10):457-466 (2016). PMID: 27578889
  • [13] Lo, M. et al. J Biol Chem, 292(9):3900-3908 (2017). PMID: 28077575
  • [14] Edavettal, S. et al. Med, 3(12):860-882.e15 (2022). PMID: 36257298
  • [15] Moore G.L. et al., Mabs, 2:181-189 (2010). PMID: 20150767
  • [16] Diebolder C.A. et al., Science, 343:1260-1263 (2014). PMID: 24626930
  • [17] Dall'Acqua, W. F. et al., J Biol Chem, 281(33):23514-23524 (2006). PMID: 16793771
  • [18] Dall'Acqua WF et al. J Immunol, 169(9):5171-80 (2002). PMID: 12391234
  • [19] Alegre M.L. et al., J. Immunol, 148:3461-3468 (1992). PMID: 1534096
  • [20] Zalevsky J. et al. Nat Biotechnol, 28:157-159 (2010). PMID: 20081867
  • [21] Chu S.Y. et al. Mol Immunol 45, 3926-3933 (2008). PMID: 18691763
  • [22] Ridgway J.B. et al. Prot Eng, 9(7):617-21 (1996). PMID: 8844834
  • [23] Thompson P. et al. J Control Release, 28(236):100-16 (2016). PMID: 27327768
  • [24] Dimasi N. et al., Mol Pharm, 14(5):1501-1516 (2017). PMID: 28245132
  • [25] Wang X. et al., Protein Cell, 9(1):63-73 (2018). PMID: 28986820
  • [26] Atwell S., et al., J Mol Biol, 270(1):26-35 (1997). PMID: 9231898
  • [27] Tammen A. et al., J Immunol, 198(4):1585-1594 (2017). PMID: 28062698
  • [28] Hinton P.R. et al. J Immunol, 176(1):346-56 (2006). PMID: 16365427
  • [29] Shang L. et al., J Biol Chem, 289(22), 15309-15318 (2014). PMID: 24737331
  • [30] Vafa O. et al., Methods, 65:114-126 (2014). PMID: 23872058
  • [31] Leoh L. S. et al., Cancer Res, 2015;75(15 Suppl):Abstract nr1335. AM2015-1335
  • [32] Li Y et al., J Immunother Cancer, 6(1):31 (2018). PMID: 29712568
  • [33] Zhou Q. et al., Pharmaceuticals, 14(7):672 (2021). PMID: 34358098
  • [34] Weitzenfeld P. et al., J Clin Invest, 129(9):3952-3962 (2019). PMID: 31424423
  • [35] Vaccaro C. et al., Proc Natl Acad Sci USA, 103(49):18709-18714 (2006). PMID: 17116867
  • [36] Brinkhaus M. et al., J Immunol, 205:3456-3467 (2020). PMID: 33188070
  • [37] Sazinsky S. L. et al., Proc Natl Acad Sci USA, 105(51):20167-20172 (2008). PMID: 19074274
  • [38] Borrok M.J. et al., J Pharm Sci, 106(4):1008-1017 (2017). PMID: 28057542
  • [39] Estes B. et al., iScience 24(12):103447 (2021). PMID: 34877503
  • [40] Li X. et al., Mol Cancer Ther, 22(2):155-167 (2023). PMID: 36459691
  • [41] Wilkinson I. et al., PLoS One, 16(12):e0260954 (2021). PMID: 34932587
  • [42] US patent 10,744,204 B2 (Aug. 18, 2020).
  • [43] Labrijn A.F. et al., Nat Rev Drug Discov, 18:585-608 (2019). PMID: 31175342
  • [44] Von Kreudenstein T.S. et al., MAbs, 5(5):646-54 (2013). PMID: 23924797
  • [45] US patent 2020/0148779-A1 (May 14, 2020).
  • [46] Baudino L. et al., J Immunol, 181(9):6664-9 (2008). PMID: 18941257
  • [47] Kenanova V. et al. Cancer Res, 65(2):622-31 (2005). PMID: 15695407
  • [48] Ye S. et al., Cancer Immunol Res, 7(11):1864-1875 (2019). PMID: 31462409
  • [49] Rogel A. et al., JCI Insight, 7(19):e158444 (2022). PMID: 35998045
  • [50] Merchant A. M. et al., Nature biotechnology, 16(7):677-681 (1998). PMID: 9661204
  • [51] Labrijn A. F. et al., Proc Natl Acad Sci USA, 110(13):5145-50 (2013). PMID: 23479652
  • [52] Riether C. et al., Nat Med 26(9):1459-1467 (2020). PMID: 32601337
  • [53] US patent 9,028,826-B2 (May 12, 2015).
  • [54] European Patent 2,282,770-A2 (Feb. 16, 2011).
  • [55] Grevys A. et al., J Immunol, 194(11):5497-508 (2015). PMID: 25904551
  • [56] Patent WO 2020/076977-A2 (Ap. 16, 2020).
  • [57] Alvarado D. et al., Allergy, 77(8):2393-2403 (2022). PMID: 35184297
  • [58] US patent 10,654,916-B2 (May 19, 2020).
  • [59] Liu R. et al., Antibodies, 9(4):64 (2020). PMID: 33212886
  • [60] Fukuzawa T. et al., Sci Rep, 7(1):1080 (2017). PMID: 28439081
  • [61] US patent 2018/039120 (Dec. 27, 2018).
  • [62] US patent 10,358,492 (Sep. 27, 2013).
  • [63] Saxena A. et al., Front Immunol, 7:580 (2016). PMID: 28018347
  • [64] Chenoweth A. M. et al., Immunol Cell Biol, 98(4):287-304 (2020). PMID: 32157732
  • [65] Moore G. L. et al., Methods, 154:38-50 (2019). PMID: 30366098
  • [66] De Nardis C. et al., J Biol Chem, 292(35):14706-14717 (2017). PMID: 28655766
  • [67] Kaplon H. et al., MAbs, 15(1):2153410 (2023). PMID: 36472472
  • [68] Patent WO 2018/090950 (May 24, 2018).
  • [69] Vaccaro C. et al., Nat Biotechnol, 23:1283-1288 (2005). PMID: 16186811
  • [70] Gunasekaran K. et al., J Biol Chem, 285(25):19637-46 (2010). PMID: 20400508
  • [71] Wei H. et al., Oncotarget, 8(31):51037-51049 (2017). PMID: 28881627
  • [72] Patent WO 2023/218100-A1 (Nov. 16, 2023).
  • [73] Maeda A. et al., MAbs, 9(5):844-853 (2017). PMID: 28387635
  • [74] Patent WO 2017/040380-A2 (March 9, 2017).
  • [75] Lefranc M. P., Lefranc G., Antibodies, 11(4):65 (2022). PMID: 36278618
  • [76] US patent 2019/0010232-A1 (Jan. 10, 2019).
  • [77] Stapleton N.M. et al., Nat Commun, 2:599 (2011). PMID: 22186895
  • [78] An Z. et al., MAbs, 1:572-579 (2009). PMID: 20073128
  • [79] Hinton P. R. et al., J Biol Chem, 279(8):6213-6216 (2004). PMID: 14699147
  • [80] Saito S. et al., Protein Sci, 29:1186-1195 (2020). PMID: 32142185
  • [81] Armour K.L. et al., Eur J Immunol, 29(8):2613-24 (1999). PMID: 10458776
  • [82] Brinkmann U., Kontermann R. E., MAbs, 9(2):182-212 (2017). PMID: 28071970
  • [83] European Patent 2,526,967-A1 (Nov., 28, 2012).
  • [84] US patent 10,653,791-B2 (May, 19, 2020).
  • [85] Liu Z. et al., J Biol Chem, 289(6):3571-90 (2014). PMID: 24311787
  • [86] US patent 2006/0134105-A1 (Jun. 22, 2006).
  • [87] Natsume A. et al., Cancer Res, 68:3863-3872 (2008). PMID: 18483271
  • [88] Tao M. H. et al., J Exp Med, 178(2):661-667 (1993). PMID: 8340761
  • [89] Zhong X. et al. J Cancer Immunol. 4(2):65-70 (2022).
  • [90] Labrijn A. F. et al., Nat Biotechnol, 27(8):767-771 (2009). PMID: 19620983
  • [91] Labrijn A. F. et al., J. Immunol, 187(6):3238-3246 (2011). PMID: 21841137
  • [92] Vergoossen D. L. E. et al., Proc Natl Acad Sci USA, 118(13):e2020635118 (2021). PMID: 33753489
  • [93] Dumet C. et al., MAbs, 11(8):1341-1350 (2019). PMID: 31556789
  • [94] Zhang J. et al., Mabs, 12(1):1724751 (2020). PMID: 32106752
  • [95] US patent 9,988,450-B2 (Jun. 5, 2018).
  • [96] Oganesyan V. et al. 64:700-4 (2008). PMID: 18560159
  • [97] Steinhardt J. et al., Pharmaceutics, 12(1):3 (2019). PMID: 31861347
  • [98] Patent WO 2018/1566740-A1 (Aug. 30, 2018).
  • [99] Skidmore L. et al. Mol Cancer Ther. 19(9):1833-1843 (2020). PMID: 32669315
  • [100] Duncan A. R. et al., Nature, 332(6164):563-564 (1988). PMID: 2965792
  • [101] Duncan A. R., Winter G., Nature, 332(6166):738-740 (1988). PMID: 3258649
  • [102] Patent WO 2015/091910-A2 (Jun. 25, 2015).
  • [103] Duivelshof B. L. et al., Talanta, 236:122836 (2022). PMID: 34635226
  • [104] Patent WO 2017/205014-A1 (Nov. 30, 2017).
  • [105] Xu C. A. et al., MAbs, 11(7):1289-1299 (2019). PMID: 31199179
  • [106] Patent WO 2013/152860-A3 (Ap. 11, 2012).
  • [107] Patent WO 2008/022152-A2 (Feb. 21, 2008).
  • [108] Joshi K. K. et al., MAbs, 11(7):1254-1265 (2019). PMID: 31286843
  • [109] Junutula J. et al., Nat Biotechnol, 26:925-932 (2008). PMID: 18641636
  • [110] Patent WO 2009/010290-A2 (Jan. 22, 2009).
  • [111] Mueller J. P. et al., Mol Immunol, 34:441-452 (1997). PMID: 9307060
  • [112] Abrahams C.L. et al. Oncotarget, 28;9(102):37700-37714 (2018). PMID: 30701025
  • [113] Lefranc MP, Lefranc G. Immunol Rev. 00: 1-34 (2024). PMID: 39367563
  • [114] Hale G. et al. mAbs 16(1):2402701 (2024). PMID: 39279104
  • [115] Patent WO 2008/129124-A1 (Oct. 30, 2008).
  • [116] Cole M.S. et al. J Immunol. 159(7):3613-21 (1997). PMID: 9317161

    • IMGT Home page | IMGT Repertoire (IG and TR) | IMGT Repertoire (MH) | IMGT Repertoire (RPI) | IMGT Index | IMGT Scientific chart | IMGT Education | IMGT Latest news rss

    CNRS Université de Montpellier European Commission

    © Copyright 1995-2025 IMGT®, the international ImMunoGeneTics information system® | Terms of use | About us | Contact us | Citing IMGT